01. Gene therapy Boulikas.pdf - Gene therapy & Molecular Biology

Folkman J and Klagsbrun M (1987) Angiogenic factors. Science
235, 442-447.
Fong G, Rossant J, Gertsenstein M, and Breitman ML (1995)
Role of the Flt-1 receptor tyrosine kinase in regulating the
assembly of vascular endothelium. Nature 376, 66-70.
Forrester WC, van Genderen C, Jenuwein T, and Grosschedl R
(1994) Dependence of enhancer-mediated transcription of
the immunoglobulin m gene on nuclear matrix attachment
regions. Science 265, 1221-1225.
Foster BJ and Kern JA (1997) HER2-targeted gene transfer.
Hum Gene Ther 8, 719-727.
Frederich RC, Hamann A, Anderson S, Lollmann B, Lowell BB,
Flier JS (1995) Leptin levels reflect body lipid content in
mice: evidence for diet-induced resistance to leptin action.
Nat Med 1, 1311-1314.
Fredman JN and Engler JA (1993) Adenovirus precursor to
terminal protein interacts with the nuclear matrix in vivo and
in vitro. J. Virol. 67, 3384-3395.
Friedman PN, Kern SE, Vogelstein B, Prives C (1990) Wild-type
but not mutant p53 proteins inhibit the replication activities
of simian virus 40 large tumor antigen. Proc Natl Acad Sci
USA 87, 9275-9279.
Friedmann T (1992) Gene therapy of cancer through restoration
of tumor-suppressor functions? Cancer 70, 1810-1817.
Friedmann T, Yee J-K (1995) Pseudotyped retroviral vectors for
studies of human gene therapy. Nature Med 1, 275-277.
Fritz JD, Herweijer H, Zhang G, and Wolff JA (1996) Gene
transfer into mammalian cells using histone-condensed
plasmid DNA. Hum Gene Ther 7, 1395-1404.
Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm
EA, and Roth JA (1994) Therapeutic effect of a retroviral
wild-type p53 expression vector in an orthotopic lung cancer
model. J Natl Cancer Inst 86, 1458-1462.
Fukumoto S, Nishizawa Y, Hosoi M, Koyama H, Yamakawa K,
Ohno S, Morii H (1997) Protein kinase C δ inhibits the
proliferation of vascular smooth muscle cells by suppressing
G1 cyclin expression. J Biol Chem 272, 13816-13822.
Galipeau J, Benaim E, Spencer HT, Blakley RL, Sorrentino BP
(1997) A bicistronic retroviral vector for protecting
hematopoietic cells against antifolates and P-glycoprotein
effluxed drugs. Hum Gene Ther 8, 1773-1783.
Gannon JV, Lane DP (1987) p53 and DNA polymerase a
compete for binding to SV40 T antigen. Nature 329, 456-
458.
Gao X, Huang L (1991) A novel cationic liposome reagent for
efficient transfection of mammalian cells. Biochem Biophys
Res Commun 179, 280-285.
Gassmann M, Donoho G, and Berg P (1995) Maintenance of an
extrachromosomal plasmid vector in mouse embryonic stem
cells. Proc Natl Acad Sci USA 92, 1292-1296.
Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D,
Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA,
Volpert O, Bouck N, Soff GA (1997) The mechanism of
cancer-mediated conversion of plasminogen to the
angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA
94, 10868-10872.
Boulikas: An overview on gene therapy
140
Gavaghan H (1995) A shot in the arm for gene therapy company.
Nature Med 1, 392.
Geller AI and Freese A (1990) Infection of cultured central
nervous system neurons with a defective herpes simplex
virus 1 vector results in stable expression of Escherichia coli
β-galactosidase. Proc Natl Acad Sci USA 87, 1149-1153.
Georgiev GP, Kiselev SL and Lukanidin EM (1998) Genes
involved in the control of tumor progression and their
possible use for gene therapy. Gene Ther Mol Biol 1, 381-
398.
Gerontakis S, Strasser A, Metcalf D, Grigoriadis G, Scheerlinck
J-PY, and Grumont RJ (1996) Rel-deficient T cells exhibit
defects in production of interleukin 3 and granulocytemacrophage
colony-stimulating factor. Proc Natl Acad Sci
USA 93, 3405-3409.
Gerrard AJ, Hudson DL, Brownlee GG, Watt FM (1993)
Towards gene therapy for haemophilia B using primary
human keratinocytes. Nature Genet 3, 180-183.
Ghitescu L, Fixman A, Simionescu M and Simionescu N (1986)
Specific binding sites for albumin restricted to plasmalemmal
vesicles of continuous capillary endothelium: Receptormediated
transcytosis. J Cell Biol 102, 1304-1311.
Ghivizzani SG, Lechman ER, Tio C, Mulé KM, Chada S,
McCormack JE, Evans CH, and Robbins PD (1997) Direct
retrovirus-mediated gene transfer to the synovium of the
rabbit knee: implications for arthritis gene therapy. Gene
Ther 4, 977-982.
Gilardi P, Courtney M, Pavirani A, Perricaudet M (1990)
Expression of human α 1-antitrypsin using a recombinant
adenovirus vector. FEFS Lett 267, 60-62.
Gilboa E (1996) Immunotherapy of cancer with genetically
modified tumor vaccines. Semin Oncol 23, 101-107.
Gilboa E and Smith G (1994) Gene therapy for infectious
diseases: The AIDS model. Trends Genet 10, 139-144.
Gilgenkrantz H, Duboc D, Juillard V, Couton D, Pavirani A,
Buillet JG, Briand P, Kahn A (1995) Transient expression of
genes transferred in vivo into heart using first-generation
adenoviral vectors: Role of the immune response. Hum
Gene Ther 6, 1265-1274.
Gillio Tos A, Cignetti A, Rovera G, Foa R (1996) Retroviral
vector-mediated transfer of the tumor necrosis factor α gene
into human cancer cells restores an apoptotic cell death
program and induces a bystander-killing effect. Blood 87,
2486-2495.
Gilmour SK, Verma AK, Madara T, and O'Brien TG (1987)
Regulation of ornithine decarboxylase gene expression in
mouse epidermis and epidermal tumors during two stage
tumorigenesis. Cancer Res 47, 1221-1225.
Ginsberg D, Mechta F, Yaniv M, Oren M (1991) Wild-type p53
can down-modulate the activity of various promoters. Proc
Natl Acad Sci USA 88: 9979-9983.
Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN,
Dillmann WH, Mathieu-Costello O, Hammond HK (1995)
Intracoronary gene transfer of fibroblast growth factor-5
increases blood flow and contractile function in an ischemic
region of the heart. Nature Med 2, 534-539.